Education
About Us
Working with TipRanks
Follow Us
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989)
:9989
9989 Stock Chart & Stats
HK$5.19
HK$0.02(0.54%)
At close: 4:00 PM EST
HK$5.19
HK$0.02(0.54%)
Day’s Range― - ―
52-Week RangeHK$3.93 - HK$7.26
Previous CloseN/A
Volume172.00K
Average Volume (3M)1.16M
Market Cap
HK$18.17B
Enterprise ValueHK$16.30B
Total Cash (Recent Filing)HK$3.08B
Total Debt (Recent Filing)HK$3.08B
Price to Earnings (P/E)17.2
Beta0.95
Next Earnings
Mar 31, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend Yield5.23%
Share Statistics
EPS (TTM)0.10
Shares Outstanding220,094,500
10 Day Avg. Volume947,650
30 Day Avg. Volume1,161,300
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.45
Price to Sales (P/S)1.03
P/FCF Ratio2.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageA low debt-to-equity (~0.25) materially enhances financial resilience, reducing refinancing and liquidity risk. This conservative leverage profile supports steady investment in compliance, capacity and R&D for heparin/API production, enabling durable operations and strategic optionality over the medium term.
Solid Cash GenerationFree cash flow exceeding net income (~1.17x) signals earnings quality and reliable cash conversion. Strong FCF provides sustainable funding for capex, regulatory compliance, dividend support and debt reduction, which are vital for capital-intensive pharma manufacturing and long-term competitiveness.
Return To Profitability & Revenue GrowthA return to profitability and ~5% TTM revenue growth indicates recovery in core heparin demand. Combined API, finished-dosage and CDMO businesses offer diversified, repeatable revenue streams that underpin medium-term cash generation and reduce reliance on any single channel or contract.
Bears Say
Margin CompressionCompression of gross and net margins reduces intrinsic earnings power and constrains free cash available for reinvestment or distributions. If margin pressure is structural—due to pricing, raw-material or mix shifts—it will impair long-term profitability and limit funding for growth or quality compliance investments.
Volatile Results HistoricallyPronounced volatility (sharp 2023 downturn then uneven recovery) weakens forecastability and complicates medium-term planning. For a manufacturing and regulatory-heavy pharma business, inconsistent earnings make capital-allocation decisions and investment in capacity or new registrations riskier for sustaining long-run growth.
Modest Shareholder Returns / Low ROEPersistently low return on equity suggests the company is not efficiently converting its equity base into strong profits. Over the medium term, modest ROE can limit shareholder value creation, constrain dividend growth and indicate operational or capital-intensity challenges relative to peers.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H News
9989 FAQ
What was Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price range in the past 12 months?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H lowest stock price was HK$3.93 and its highest was HK$7.26 in the past 12 months.
What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s market cap?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s market cap is HK$18.17B.
When is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s upcoming earnings report date?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s upcoming earnings report date is Mar 31, 2026 which is in 36 days.
How were Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s earnings last quarter?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H released its earnings results on Oct 30, 2025. The company reported HK$0.098 earnings per share for the quarter, the consensus estimate of HK$0.098 by HK$0.
Is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H overvalued?
According to Wall Street analysts Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price is currently Overvalued.
Does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pay dividends?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pays a Annually dividend of HK$0.272 which represents an annual dividend yield of 5.23%. See more information on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H dividends here
What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s EPS estimate?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s EPS estimate is -0.17.
How many shares outstanding does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H have?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has 220,094,500 shares outstanding.
What happened to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price movement after its last earnings report?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H reported an EPS of HK$0.098 in its last earnings report, expectations of HK$0.098. Following the earnings report the stock price went down -0.372%.
Which hedge fund is a major shareholder of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9989
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.12%
12-Months-Change
Fundamentals
Return on Equity
3.31%
Trailing 12-Months
Asset Growth
-6.28%
Trailing 12-Months
Company Description
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) Earnings & Revenues
Technical Analysis
HUTCHMED (China)
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―
―
CanSino Biologics, Inc. Class H
―
Options Prices
Currently, No data available
---